APRN, DNP
Chad Sanders
Education
- Doctor of Nursing Practice – University of Kentucky, Lexington, KY
- Master of Science Nursing – Western Kentucky University, Bowling Green, KY
- Bachelor of Science Nursing – Western Kentucky University, Bowling Green, KY
Board Certification
- American Nurses Credentialing Center
- Family Nurse Practicioner
- American Heart Association
Licensure
- Kentucky RN: 1091744K
- Kentucky APRN: 3004263
- NPI#: 1104857432
Medical Experience
- Principal Investigator, Sub-Investigator, Nurse Practitioner - Research Integrity LLC
- Nurse Practitioner - Immediate Care Center
- APRN - Ohio County Hospital/ Quick Care Clinic
- Nurse Practitioner - Team Health/ Medical Center
- Nurse Practitioner - Comprehensive Neurosurgical Associates
- Family Nurse Practitioner - ECHO Community Health Care
- Registered Nurse - Medical Center: Intensive Care Unit
- Registered Nurse - St. Thomas Health System
- 91B/Medical Specialist/Aide-Evac NCO SCT/E-5 - Kentucky Army National Guard
- Paramedical Examiner - Hooper Homes, Inc.
Clinical Research Experience
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)
- A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Asses the Efficacy and Safety of REL-1017 Monotherapy for Major Depressive Disorder (The RELIANCE-III Study)
- A Phase 3, Multicenter, Open-Label Study to Asses the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder (RELIANCE-OLS)
- A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obcetrapib 10 mg Daily in Combination with Ezetimibe 10 mg Daily as an Adjunct to High Intensity Statin Therapy: The ROSE Study
- Obicetrapib on Top Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants with Underlying HeFH and/or Atherosclerotic Cardiovascular Disease (ASCVD) Who Are Not Adequately Controlled by Their Lipid-Modifying Therapies. TA-8995-302 Broadway
- Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
- A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Prevention of COVID-19 (EVADE)
- A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with open-Label Rivaroxaban in Patients with Atrial Fibrillation ANT-006
- A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Asses the Efficacy, Safety, and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2 CKD
- A Phase 1a/b Randomized, Single-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Single Ascending Doses of AZD3427 in Patients with Heart Failure (HFrEF and HFpEF)
- A Randomized Double-Blind, Placebo-controlled Study of SEL-212 in Patients with Gout Refractory to Conventional Therapy: Selecta
- A Phase III Randomized, Double-Blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, A Combination Product of Two Monoclonal Antibodies ( AZD8895 and AZD1061), for Post-exposure Prophylaxis of COVID-19: Storm Chaser
- A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisirin Sodium Given as Subcutaneous Injections in Subjects with Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-density Lipoprotein Cholesterol (LDL-C) - MDCO-ORION
- A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute Migraine in Patients with Stable Vascular Disease. M34
- A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Sage 547-PPD-202 Injection in the Treatment of Adult Female Subjects with Severe Postpartum Depression and Adult Female Subjects with Moderate Postpartum Depression. SAGE 547-PPD-202
- A Phase III, Multi-center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of K-103-IP Compared to Placebo for the Treatment of Mild to Moderate Acute Pain Associated with Ankle Sprain or Sprain. KOWA
- A 52 week, Open Label Evaluation of the Effects of sacubitril/valsartan (LCZ696) therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failures with Reduced Left Ventricular Ejection Fraction (PROVE-HF)
- A Phase 2, Multi-center, Placebo controlled, Randomized, Double-blind, 12 week Study with a 40 Week, Active controlled, Double-blind, Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients with Fasting Triglyceride Levels > 500mg/dL and <2000 mg/dL and Normal Renal Function
- A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Asses the Clinical and Health Outcomes of Toujeo compared tp Commercially Available Basal Insulins for Initiation of Therapy in Insulin Naïve Patients with Uncontrolled Type 2 Diabetes Mellitus. LPS14347
- A Multi-Center, Randomized, Double-Blind, Placebo- and Active - Controlled, Crossover Study to Evaluate the Safety and Efficacy of MK-0974 in the Treatment of Acute migraine in Patients with Stable Vascular Disease
- An Open-label, Parallel-group, Randomized, Multi-center Study to Assess the Safety and Efficacy of Vilaprisan in Subjects with Uterine Fibroid Versus Standard of Care
- A Phase 3, Randomized, Open-label, Comparative Safety and Efficacy Trial of intravenous Iron Isomaltoside (Monofer) and Iron Sucrose in Subjects with Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease. CKD-04
- A Phase 3, Randomized, open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside (Monofer) and Iron Sucrose in Subjects with Iron Deficiency Anaemia Who Are Intolerant or Unresponsive to Oral Iron Therapy Or in Whom the Hemoglobin Measurement in Investigators Opinion were Sufficiently Low as to Require Rapid Repletion of Iron Stores to Minimize the Risk of Receiving a Blood Transfusion. P-Monofer-IDA-03
- A Randomized, Double-blind, Parallel-group, Placebo and Active-controlled, Multi-center Phase 3 Study to Evaluate the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methatrexate Therapy. CREDO
- A Randomized, Double-blind, Parallel-group, Placebo-and-Active-Controlled, Multicenter Phase 3 Study of Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely ACTIVE Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy. CREDO3
- A Multi-center, Open-label, Phase 3 Study of Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely ACTIVE Rheumatoid Arthritis. CREDO4
- A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism. Amplify
- A Phase 3, Active (Warfarin) Controlled, Randomized, Double-blind, Parallel-Arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Nonvascular Atrial Fibrillation. Aristotle
- A Double-Blind, Placebo-Controlled, Multi-Center Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure. Ascend
- A Randomized, Double-Blind, Double-Dummy, Parallel Group, Phase 3 Efficacy and Safety Study of CGT-2168 Compared with Clopidogrel to Reduce the Incidence of Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease. Cogent
- A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early front-Loaded Eptifbatide in the Treatment of Patients with Non-St-Segment Elevation cute Coronary Syndrome. Early ACS
- A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients with Elevated haCRP. No2301
- A Multi-Center, Randomized, Placebo-Controlled, Double-Blnded Study of the Efficacy and Safety of Lubiprostone in Subjects with Opiod-Induced Bowel Dysfunction. Suc
- A Randomized, Double-Blind, Active-Controlled Study of Canakinumab (ACZ885) Prefilled Syringes or Reconstituted Lyophilizate Versus Triamcinolone Acetonide for Treating Acute Gouty Arthritis Flares in Frequently Flaring Patients. No2361
- A Phase 3b, Multi-Center, Open-Label Study to Evaluate the Long term Safety and Efficacy of LY2127399 in Patients with Rheumatoid Arthritis (RA). LBCDP
- A Phase 3b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had Inadequate Response to One or More TNF-a Inhibitors. LBCDV
- A Phase 3b, 24-Week, Randomized, Placebo-Controlled, Double-Blinded, Efficacy and Safety Study of Linagliptin in Black/African American Patients with Type II Diabetes with MMT Sub-Study. BR1218
- A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Repeat-Dose, Oral, Dose-Ranging Study to Asses the Safety and efficacy of Plecanatide in Patients with Chronic Idiopathic Constipation. Synergy
- Acute Bacterial Otitis Externa. Novum AOE
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.